Opening stock page...
Fetching company snapshot, pricing, and intelligence.
Intelligence coverage: 65%
Basic profile, financials, and market data are shown below. Deep research is building in the background.
AI confidence 70% · prior close shown (market closed)
3 signals not yet derived from pipeline evidence
Pipeline evidence · 15d ago
GANX's AlphaOS Signals
Upgrade to Pro for validated historical pattern analysis on GANX.
Free accounts see more of this; Premium sees all of it.
Updated
What happened recently for Gain Therapeutics, Inc. (GANX) — events, not interpretation.
Research & analysis only — not investment advice.
Investment snapshot
GANX's AI investment thesis
Upgrade to Premium for GANX's full multi-agent investment thesis.
Free accounts see more of this; Premium sees all of it.
Unified data coverage and cross-signal highlights — market, SEC, earnings, opportunity
Strengthen intelligence
Prior close
$1.78
Market cap
$77.69M
Profitable
—
Net income
—
FY Sep 1, 2026
Loading Wall Street consensus…
Loading earnings intelligence…
Building technical intelligence snapshot — check back shortly.
Loading market context…
No price history. Sync market data to load charts.
Loading SEC filing intelligence…
No filings ingested yet.
Investment Snapshot above is the primary AlphaOS analysis for Gain Therapeutics, Inc. — structured signals and evidence from proprietary pipelines, not an encyclopedia overview.
Research & analysis only — not investment advice. Price, charts, and filings are above.
Follow Gain Therapeutics, Inc. through AlphaOS's knowledge graph — themes, peers, beneficiaries, earnings, and research answers.
Connected companies and research pages from the AlphaOS knowledge graph.